Search - tctmd.com

Displaying 21 - 34 of 34

Sort: Relevancy | Date

News Daily News

TCTMD’s Top 10 Most Popular Stories for March 2021

Shelley Wood

April 02, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

FDA Approves Shockwave Intravascular Lithotripsy for Calcified Coronaries

Shelley Wood

February 16, 2021

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

Todd Neale

August 19, 2019

News Daily News

FDA Approves New Covered Stent Option for Coronary Perforations

Todd Neale

September 14, 2018

News Daily News

CV Devices in the Fast Lane: FDA’s Approval Often Rests on Early Evidence

Caitlin E. Cox

September 05, 2018

News Daily News

FDA Grants HeartWare LVAD a Destination Therapy Indication

Todd Neale

September 28, 2017

News Daily News

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

Shelley Wood

June 05, 2017

News Industry News

Corindus Vascular Robotics Receives FDA Clearance for Next Generation Robotic System

October 27, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

Advertisement

TCTMD’s Top 10 Most Popular Stories for March 2021

Roughly 80% of ESC Guideline Writers Have Financial COIs

FDA Approves Shockwave Intravascular Lithotripsy for Calcified Coronaries

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

FDA Approves Baroreflex Activation Therapy Device for Advanced Heart Failure

FDA Approves New Covered Stent Option for Coronary Perforations

CV Devices in the Fast Lane: FDA’s Approval Often Rests on Early Evidence

FDA Grants HeartWare LVAD a Destination Therapy Indication

FDA Clears Sentinel Cerebral Protection Device for Use During TAVR

Corindus Vascular Robotics Receives FDA Clearance for Next Generation Robotic System

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content